|1.||Darlington, Cynthia L: 1 article (07/2005)|
|2.||Crowe, P D: 1 article (11/2000)|
|3.||Qin, Y: 1 article (11/2000)|
|4.||Conlon, P J: 1 article (11/2000)|
|5.||Antel, J P: 1 article (11/2000)|
07/01/2005 - "Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. "
11/01/2000 - "We assessed the immune response induced in multiple sclerosis (MS) patients who had received NBI-5788, an altered peptide ligand (APL) designed from an immunodominant region (83-99) of the neuroantigen myelin basic protein (MBP) (5, 10, or 20 mg subcutaneously weekly for 4 weeks). "
11/01/2000 - "NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients."